scholarly journals PRS15 COMPARISON OF HOSPITALIZATION RATES AND LIMITATION OF DAILY ACTIVITIES IN SEVERE ASTHMA PATIENTS RECEIVING BIOLOGIC AND NON-BIOLOGIC TREATMENT REGIMENS

2019 ◽  
Vol 22 ◽  
pp. S875
Author(s):  
A. Kyle ◽  
B.Y. Cheng ◽  
N.B. Yaacob ◽  
S. Brown
Keyword(s):  
Severe Asthma ◽  
Daily Activities ◽  
Biologic Treatment ◽  
Treatment Regimens ◽  
Hospitalization Rates ◽  
Asthma Patients

scholarly journals Impact on hospitalization rates as a result of the implementation of a care programme for severe asthma patients in Espirito Santo, Brazil

2015 ◽  
Vol 8 ◽  
pp. A224
Author(s):  
Lyvia Barbosa Alves ◽  
Maria José Sartório ◽  
Faradiba Serpa ◽  
Rayane Fontoura Koch ◽  
Braga Neto ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Care Programme ◽  
Espírito Santo ◽  
Hospitalization Rates ◽  
Asthma Patients ◽  
Espirito Santo

scholarly journals Review of Single Centre Experience with Bronchial Thermoplasty in Obesity

2021 ◽  
Author(s):  
EKAMJEET RANDHAWA ◽  
Kartik Shenoy
Keyword(s):  
Severe Asthma ◽  
Average Weight ◽  
Loss Reduction ◽  
Hospitalization Rates ◽  
Post Procedure ◽  
Single Centre Experience ◽  
Before And After ◽  
Asthma Patients ◽  
Oral Steroids ◽  
Predominantly Female

Abstract BackgroundBronchial thermoplasty (BT) is a bronchoscopic procedure that aims to reduce symptoms in patients with severe asthma by delivering controlled radiofrequency activations to reduce airway smooth muscle mass who are uncontrolled despite adequate therapy.ObjectiveTo evaluate response and outcomes of BT in asthma patients with obesity.MethodsA retrospective review of patients who had BT for severe asthma performed at our institution. We examined baseline differences in eosinophil, IgE levels, controller agent uses before and after BT, symptomatology and exacerbation rates post-procedure. A comparative analysis was done using t-test for unequal variables for those reported to have benefitted from the procedure against those who did not.ResultsIn total 23 patients were studied, 18 (78%) noted benefit from BT. Patients were predominantly female, 21/23 (91%) with average BMI of 37.9 and 35.3 kg/m2 in improved and not improved groups. Patients with improvement following completion of all three BT procedures were likely to be weaned off chronic oral steroids or biologicals, reduced albuterol uses, report a subjective improvement in symptoms or reduced exacerbations within 1 year following completion of procedures. There was a statistically significant average weight loss reduction in the improved group compared to not benefitted of 6.4kg versus a gain of 2.5kg; hospitalization rates for exacerbations were higher than those reported in the AIR2 and PAS2 studies at 43%.ConclusionBT can be beneficial for obese patients with a potential decrease in exacerbations and reduced oral corticosteroid dosage and an anticipated increased rate of post-procedure exacerbation hospitalization.

scholarly journals COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control

Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 853
Author(s):  
Marco Caminati ◽  
Gabriella Guarnieri ◽  
Veronica Batani ◽  
Elena Scarpieri ◽  
Anita Finocchiaro ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Disease Control ◽  
Severe Asthma ◽  
Vaccination Campaign ◽  
Tolerability Profile ◽  
Life Questionnaire ◽  
Biologic Treatment ◽  
Asthma Patients

Background: COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient’s quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment. Methods: Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ). Results: Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration. Conclusions: Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.

Baseline characteristics of severe asthma patients initiating biologic treatment worldwide

2021 ◽  
Author(s):  
Luis Pérez De Llano ◽  
Aivaras Cepelis ◽  
Trung Tran ◽  
Ruth Murray ◽  
David Price ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Biologic Treatment ◽  
Asthma Patients ◽  
Baseline Characteristics

scholarly journals Comparing Patient Characteristics, Clinical Outcomes, and Biomarkers of Severe Asthma Patients in Taiwan

Biomedicines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 764
Author(s):  
Shih-Lung Cheng ◽  
Kuo-Chin Chiu ◽  
Hsin-Kuo Ko ◽  
Diahn-Warng Perng ◽  
Hao-Chien Wang ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Clinical Characteristics ◽  
Linear Models ◽  
Patient Characteristics ◽  
Emergency Department Visits ◽  
Receiver Operating Characteristic Curves ◽  
Increased Risk ◽  
Significant Difference ◽  
Asthma Patients ◽  
Patients At Risk

Purpose: To understand the association between biomarkers and exacerbations of severe asthma in adult patients in Taiwan. Materials and Methods: Demographic, clinical characteristics and biomarkers were retrospectively collected from the medical charts of severe asthma patients in six hospitals in Taiwan. Exacerbations were defined as those requiring asthma-specific emergency department visits/hospitalizations, or systemic steroids. Enrolled patients were divided into: (1) those with no exacerbations (non-exacerbators) and (2) those with one or more exacerbations (exacerbators). Receiver operating characteristic curves were used to determine the optimal cut-off value for biomarkers. Generalized linear models evaluated the association between exacerbation and biomarkers. Results: 132 patients were enrolled in the study with 80 non-exacerbators and 52 exacerbators. There was no significant difference in demographic and clinical characteristics between the two groups. Exacerbators had significantly higher eosinophils (EOS) counts (367.8 ± 357.18 vs. 210.05 ± 175.24, p = 0.0043) compared to non-exacerbators. The optimal cut-off values were 292 for EOS counts and 19 for the Fractional exhaled Nitric Oxide (FeNO) measure. Patients with an EOS count ≥ 300 (RR = 1.88; 95% CI, 1.26–2.81; p = 0.002) or FeNO measure ≥ 20 (RR = 2.10; 95% CI, 1.05–4.18; p = 0.0356) had a significantly higher risk of exacerbation. Moreover, patients with both an EOS count ≥ 300 and FeNO measure ≥ 20 had a significantly higher risk of exacerbation than those with lower EOS count or lower FeNO measure (RR = 2.16; 95% CI, 1.47–3.18; p = < 0.0001). Conclusions: Higher EOS counts and FeNO measures were associated with increased risk of exacerbation. These biomarkers may help physicians identify patients at risk of exacerbations and personalize treatment for asthma patients.

scholarly journals Trends in oral corticosteroids use in severe asthma: a 14-year population-based study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Mohsen Sadatsafavi ◽  
Amir Khakban ◽  
Hamid Tavakoli ◽  
Solmaz Ehteshami-Afshar ◽  
Larry D. Lynd ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Poisson Regression ◽  
Population Based ◽  
Population Based Study ◽  
Factors Associated ◽  
Asthma Patients ◽  
Oral Corticosteroids ◽  
Administrative Health Databases ◽  
Time Since Diagnosis

Abstract Background Oral corticosteroids are important components of pharmacotherapy in severe asthma. Our objective was to describe the extent, trends, and factors associated with exposure to oral corticosteroids (OCS) in a severe asthma cohort. Methods We used administrative health databases of British Columbia, Canada (2000–2014) and validated algorithms to retrospectively create a cohort of severe asthma patients. Exposure to OCS within each year of follow-up was measured in two ways: maintenance use as receiving on average ≥ 2.5 mg/day (prednisone-equivalent) OCS, and episodic use as the number of distinct episodes of OCS exposure for up to 14 days. Trends and factors associated with exposure on three time axes (calendar year, age, and time since diagnosis) were evaluated using Poisson regression. Results 21,144 patients (55.4% female; mean entry age 28.7) contributed 40,803 follow-up years, in 8.2% of which OCS was used as maintenance therapy. Maintenance OCS use declined by 3.8%/calendar year (p < 0.001). The average number of episodes of OCS use was 0.89/year, which increased by 1.1%/calendar year (p < 0.001). Trends remained significant for both exposure types in adjusted analyses. Both maintenance and episodic use increased by age and time since diagnosis. Conclusions This population-based study documented a secular downward trend in maintenance OCS use in a period before widespread use of biologics. This might have been responsible for a higher rate of exacerbations that required episodic OCS therapy. Such trends in OCS use might be due to changes in the epidemiology of severe asthma, or changes in patient and provider preferences over time.

scholarly journals Clinical equivalency of Beclasone Eco Easi Breathe and Flixotide via MDI in asthma patients

2007 ◽  
pp. 74-81
Author(s):  
A. A. Visel ◽  
V. N. Seliverstov ◽  
I. Yu. Visel ◽  
V. A. Sergeev ◽  
N. M. Rakhmatullina
Keyword(s):  
Severe Asthma ◽  
Comparative Trial ◽  
Similar Efficacy ◽  
Heart Beat ◽  
Inhaled Steroids ◽  
Russian Version ◽  
Asthma Patients ◽  
Heart Beat Rate ◽  
Physical Findings

It is well known that efficacy of asthma treatment depends on a choice of a basic medication as well as on a delivery system. The aim of this study was a comparison of clinical efficacy of equal doses of beclomethasone dipropionate (Beclasone Eco Easi Breathe) and fluticasone propionate (Flixotide) via MDI. The study was designed as a randomized open prospective comparative trial. Findings of 26 patients with moderate and severe asthma of > 18 yrs old were analyzed, such as medical history, physical findings, spirometric and bronchodilating test results, heart beat rate and blood pressure, quality of life (QoL) using Russian version of AQLQ questionnaire. After the run-in period the patients randomly received Beclasone Eco Easi Breathe 500 to 1000 μg daily or Flixotide at the same doses for 4 weeks followed the cross-over change of the drugs for the next 4 weeks. After 1 month of the treatment, significant improvements in airflow parameters, need in short-acting β2 -agonists and QoL have been reported. After changing the drugs these effects have been maintained with no further reliable improvement. Thus, the study demonstrated similar efficacy and safety of these inhaled steroids that could be considered as being clinically equal in treatment of moderate and severe asthma.

Sign in / Sign up

Export Citation Format

Share Document